[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT01580982":3,"trial-entities:NCT01580982":73,"trial-summary:NCT01580982":77},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":23,"primary_purpose":24,"phases":25,"enrollment_info":26,"interventions":29,"primary_outcomes":30,"secondary_outcomes":34,"sex":37,"minimum_age":38,"maximum_age":39,"healthy_volunteers":15,"eligibility_criteria":40,"std_ages":44,"locations":47,"central_contacts":66,"overall_officials":68,"references":71,"see_also_links":72},"NCT01580982","11-1621.cc","Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer","Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung and Other Thoracic Cancers","RECRUITING","2029-01-30","2026-02","2026-02-18","2012-01-23","University of Colorado, Denver","OTHER",false,"The mechanisms of sensitivity and resistance to oncogene-targeted therapy can be determined from tumor tissue or tumor cell lines derived from available archival samples and\u002For from standard-of-care re-biopsy upon suspected tumor progression.","To identify baseline and treatment-related somatic changes in the tumor tissue from patients with lung and other thoracic cancers. To estimate the proportion of patients that subsequent therapy is altered based on the information acquired from such biopsies.",[19],"Lung Neoplasms",[21,22],"Oncogenes","Lung and Other Thoracic Cancers","OBSERVATIONAL",null,[],{"count":27,"type":28},500,"ESTIMATED",[],[31],{"measure":32,"timeFrame":33},"To identify baseline and treatment-related somatic changes in the tumor tissue from patients with lung and other thoracic cancers.","To be determined upon funding",[35],{"measure":36,"timeFrame":33},"To estimate the proportion of patients that subsequent therapy is altered based on the information acquired from such biopsies","ALL","18 Years","85 Years",{"inclusion":41,"exclusion":42,"raw_text":43},[],[],"Inclusion Criteria:\n\n1. Patients undergoing investigation or treatment for thoracic cancers with oncogene-targeted therapies\n2. Aged 18 years or older\n3. Either a) have suspected tumor progression or other condition that dictates a standard-of-care palliative, therapeutic, or diagnostic intervention including but not limited to procedures such as bronchoscopic biopsy, computed tomography (CT) or ultra-sound (US)-guided biopsy, thoracentesis, video assisted thoracoscopic (VATS) pleurodesis, lobectomy, adrenalectomy or pleural catheter placement, providing tumor specimen appropriate molecular analysis or b) have previously had biopsy\u002Fsurgical intervention with tumor tissue at University of Colorado or an outside institution available for medullar analysis.\n4. Patients must have the ability to understand and willingness to sign an informed consent document.\n\nExclusion Criteria:\n\n\\-",[45,46],"ADULT","OLDER_ADULT",[48],{"facility":49,"status":8,"city":50,"state":51,"zip":52,"country":53,"contacts":54,"geoPoint":63},"University of Colorado Cancer Center","Aurora","Colorado","80045","United States",[55,60],{"name":56,"role":57,"phone":58,"email":59},"Brandi Kubala","CONTACT","303-724-1657","brandi.kubala@cuanschutz.edu",{"name":61,"role":62},"Erin Schenk, MD,Ph.D","PRINCIPAL_INVESTIGATOR",{"lat":64,"lon":65},39.72943,-104.83192,[67],{"name":56,"role":57,"phone":58,"email":59},[69],{"name":70,"affiliation":13,"role":62},"Erin Schenk, MD, PhD",[],[],{"nct_id":4,"conditions":74,"biomarkers":76},[75],"Thoracic Neoplasm",[],{"nct_id":4,"found":78,"summary":79,"prompt_version":89},true,{"design":80,"status":81,"heading":82,"summary":83,"follow_up":84,"word_count":85,"commitments":86,"compensation":87,"drugs_mentioned":88},"This is an observational study planning to include 500 participants. It aims to identify changes in tumor tissue.","completed","Molecular Analysis of Lung Cancer Oncogenes and Resistance","This study is looking at tumor tissue from people with lung and other chest (thoracic) cancers. Researchers want to understand how these cancers respond to treatments that target specific cancer genes (oncogene-targeted therapies). They will analyze tissue samples to find changes in the cancer cells both before and during treatment. This helps them learn why some treatments work and why some cancers become resistant. You may be able to join if you are 18 to 85 years old, have a thoracic cancer, and are receiving or being evaluated for oncogene-targeted therapies. The goal is to see if this information can help doctors choose better treatments for patients. The study is currently unclear on its recruitment status.","The primary endpoint will be measured at a time to be determined upon funding.",116,"Not specified in the trial record.","Not stated in the trial record.",[],"v2"]